FY2026 Earnings Forecast for TSE:ONC Issued By HC Wainwright

Oncolytics Biotech Inc. (TSE:ONC) – Analysts at HC Wainwright cut their FY2026 EPS estimates for Oncolytics Biotech in a research report issued on Wednesday, August 19th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.42) per share for the year, down from their previous forecast of ($0.39). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q4 2026 earnings at ($0.10) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.08) EPS, FY2027 earnings at ($0.29) EPS, FY2028 earnings at ($0.26) EPS and FY2029 earnings at $0.00 EPS.

Oncolytics Biotech Stock Performance

TSE ONC opened at C$14.90 on Friday. The firm has a market cap of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80. The company has a quick ratio of 8.86, a current ratio of 2.88 and a debt-to-equity ratio of 14.58. The company’s 50 day moving average is C$14.90 and its 200-day moving average is C$14.90. Oncolytics Biotech has a 12-month low of C$0.44 and a 12-month high of C$2.08.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.